Author

S. K. Tasian

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6 Immunology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 9 Assay:bulk RNA-seq· 6 Research Focus:drug response / drug discovery· 6 Approach:statistical model· 6 Approach:experimental assay· 4 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Assay:proteomics· 3

Frequent Co-Authors

J. P. Loftus· 3 shared A. Thomas-Tikhonenko· 2 shared C. D. Falkenstein· 2 shared G. Wertheim· 2 shared H. Kim· 2 shared K. E. Hayer· 2 shared K. M. Bernt· 2 shared K. Tan· 2 shared

Activity by Year

2019-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. P. Loftus

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

Z. Ang, L. Paruzzo, K. E. Hayer, C. Schmidt, M. Torres Diz, F. Xu, U. Zankharia, Y. Zhang, S. Soldan, S. Zheng, C. D. Falkenstein, J. P. Loftus, S. Y. Yang, M. Asnani, P. King Sainos, , A. Thomas-Tikhonenko

This study identifies alternative splicing of CD20 mRNA that generates translation-deficient isoforms, contributing to resistance to CD20-directed immunotherapies.

Blood · Nov 16, 2023Peer-reviewedImmunology

An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia

M. T. Diz, C. Reglero, C. D. Falkenstein, A. Castro, K. E. Hayer, C. Radens, M. Quesnel-Vallieres, Z. Ang, P. Sehgal, M. M. Li, Y. Barash, S. K. Tasian, A. Ferrando, A. Thomas-Tikhonenko

The paper identifies an alternatively spliced NT5C2 isoform contributing to chemoresistance in B-ALL by enhancing nucleosidase activity and 6-MP resistance.

bioRxiv · Sep 14, 2023Cancer Biology

Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing

T. F. Hill, P. Narvekar, G. Asher, N. Camp, K. R. Thomas, S. K. Tasian, D. J. Rawlings, R. G. James

This paper engineers human plasma cells to secrete bispecific antibodies that kill leukemia cells in vitro and in vivo, showing efficacy against B-acute lymphoblastic leukemia and acute myeloid leukemia.

bioRxiv · Aug 24, 2023 · PreprintBioengineering

Clonal evolution mediates Menin-inhibitor resistance in KMT2A-rearranged leukemias.

L. Mahdavi, H. Goodrow, F. Alikarami, A. Lenard, S. S. Riedel, C. Libbrecht, I. Bowser, S. K. Tasian, C. Falkenstein, B. Manning, S. Skuli, M. P. Carroll, G. Wertheim, S. Cai, G. McGeehan, , K. M. Bernt

This study shows that Menin-inhibitor resistance in KMT2A-rearranged leukemias arises through clonal evolution, with resistance developing without prior exposure to the inhibitor.

bioRxiv · Mar 16, 2023Cancer Biology

Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax in FLT3- and KIT- Mutant AML

B. Popescu, C. Stahlhut, T. C. Tarver, S. Wishner, B. J. Lee, C. A. C. Peretz, C. Luck, P. Phojanakong, J. A. Camara Serrano, H. Hongo, J. M. Rivera, S. Xirenayi, J. A. Chukinas, V. Steri, S. K. Tasian, , C. C. Smith

This study shows that combining SHP2 and BCL2 inhibition synergistically kills FLT3- and KIT-mutant AML cells and xenografts.

bioRxiv · Dec 1, 2022 · PreprintCancer Biology

Pharmacologic Inhibition of DYRK1A Results in MYC Hyperactivation and ERK Hyperphosphorylation rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

C. Hurtz, V. S. S. A. Ayyadevara, G. Wertheim, J. Chukinas, J. P. Loftus, S. J. Lee, A. Kumar, R. S. Bhansali, S. Swaminathan, H. Geng, T. Milne, X. Hua, K. M. Bernt, T. Besson, J. Shi, , S. K. Tasian

This study shows that inhibiting DYRK1A in KMT2A-R ALL cells leads to MYC upregulation and ERK hyperphosphorylation, making them sensitive to BCL2 inhibition.

bioRxiv · Oct 2, 2022 · PreprintCancer Biology

Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia

Y.-Y. Ding, H. Kim, K. Madden, J. P. Loftus, G. M. Chen, D. H. Allen, R. Zhang, J. Xu, Y. Hu, S. K. Tasian, K. Tan

The paper identifies synergistic genetic targets in Ph-like B-ALL using network analysis to guide combination therapy, showing improved efficacy in preclinical models.

bioRxiv · Jan 6, 2021Cancer Biology

Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers

B. He, P. Gao, Y.-y. Ding, C.-h. Chen, G. Chen, C. Chen, H. Kim, S. K. Tasian, S. P. Hunger, K. Tan

This study identifies and characterizes noncoding mutations in pediatric cancers using a computational framework and experimental validation, revealing their role in deregulating cis-regulatory landscapes.

bioRxiv · Nov 15, 2019Cancer Biology

Immune Landscapes Predict Chemotherapy Resistance And Immunotherapy Response In Acute Myeloid Leukemia

J. Vadakekolathu, M. D. Minden, T. Hood, S. E. Church, S. Reeder, H. Altmann, A. H. Sullivan, E. J. Viboch, T. Patel, N. Ibrahimova, S. E. Warren, A. Arruda, Y. Liang, J. Muth, M. Schmitz, , S. Rutella

This study identifies immune subtypes in AML and shows that IFN-gamma profiles predict chemotherapy resistance and immunotherapy response.

bioRxiv · Jul 26, 2019Immunology